CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancerR.I. Olivier, Marc van Beurden, M.A.C. Lubsen-Brandsma et al.|Gynecologic Oncology|2005Cited by 180
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyBrenda Hermsen, Matti A. Rookus, R.I. Olivier et al.|British Journal of Cancer|2007Cited by 153
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-upR.I. Olivier, Laura J. van’t Veer, Marc van Beurden et al.|British Journal of Cancer|2004Cited by 133
The role of gene expression profiling in the clinical management of ovarian cancerR.I. Olivier, Laura van ‘t Veer, Marc van Beurden|European Journal of Cancer|2006Cited by 20
Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?R.I. Olivier, Marc van Beurden, Lottie A.C. Lubsen-Brandsma et al.|Gynecologic Oncology|2004Cited by 13